Main description:

Treating Life-Threatening Bleedings: Development of Recombinant Coagulation Factor VIIa provides a comprehensive understanding of the first new drug within the area of hemostasis, describing a new mechanism of action that has resulted in a modified concept of the whole hemostasis mechanism. As the treatment of life-threatening bleedings is a serious challenge for clinicians, this powerful and historic case study presents a detailed roadmap on how a new medicine can be developed, stressing the interaction between science and clinical work.

The book stresses the importance of patient care in the learning process and provides new ideas on how to approach diseases and their treatment. Users will find a real world example that will act as a timely resource for those learning about, or engaged in, performing and supervising research across the biomedical sciences.

Contents:

1. Classical Bleeding Disease (Hemophilia) 2. My Encounter With Hemophilia (1959-82) 3. The First Years at Novo Nordisk 4. The Development of Recombinant FVIIa (rFVIIa) (1985-88) 5. The Further Use and Development of rFVIIa (1989-96) 6. Legal Issues Regarding the Use of rFVIIa in Hemophilia Patients With Inhibitors 7. Treatment With rFVIIa in Malmoe (1996-99) 8. The Launching and Uses of rFVIIa 9. Mechanism of Action and Dosage 10. The Continued Development of rFVIIa During the 2000s 11. Safety and Health Economy of rFVIIa 12. Three Different Descriptions of How rFVIIa Was Developed 13. Some Final Remarks